Form 4 for ICE Intercontinental Exchange
Accepted 2024-04-05 00:00:00 ET · period of report 2024-04-03 · accession 0000950170-24-042293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMTI | 2024-04-05 | 2024-04-03 | ICE | Sprecher Jeffrey C | CEO, Dir | S - Sale+OE | $137.21 | -110.0K | 2.67M | -4% | -$15.09M |
| DMT | 2024-04-05 | 2024-04-03 | ICE | Sprecher Jeffrey C | CEO, Dir | S - Sale+OE | $137.21 | -58.4K | 1.18M | -5% | -$8.01M |
| DT | 2024-04-05 | 2024-04-03 | ICE | Sprecher Jeffrey C | CEO, Dir | M - OptEx | $50.01 | +58.4K | 1.24M | +5% | +$2.92M |
| DT | 2024-04-05 | 2024-04-03 | ICE | Sprecher Jeffrey C | CEO, Dir | M - OptEx | $0.00 | -58.4K | 58.4K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-03 | S | D | 5,776 | $137.82 | 2,661,705 | I | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of August 7, 2023. (F7) The price range for the aggregate amount sold by the direct holder is $137.71 - $138.09. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price. (F8) As previously reported, the reporting person also indirectly owns 2,661,705 shares that are beneficially owned directly by CPEX. The reporting person beneficially owns 100% of the equity interest in CPEX. Additionally, as previously reported, the reporting person indirectly owns shares that are beneficially owned directly by the reporting person's spouse for which the reporting person disclaims beneficial ownership. |
| 2 | Common | Common Stock | 2024-04-03 | S | D | 104,224 | $137.18 | 2,667,481 | I | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of August 7, 2023. (F6) The price range for the aggregate amount sold by the direct holder is $136.71 - $137.69. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-04-03 | S | D | 3,112 | $137.83 | 1,179,895 | D | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of August 7, 2023. (F3) The price range for the aggregate amount sold by the direct holder is $137.72 - $138.04. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price. (F5) The satisfaction of the performance based restricted stock units granted as Deal Incentive Awards and the corresponding number of shares to be issued pursuant to these awards, will not be determined until December 2026, December 2027 and December 2028 and will be subject to additional time-based vesting conditions and, if applicable, a subsequent one-year holding period. (F4) The common stock number referred in Table I is an aggregate number and represents 1,110,990 shares of common stock and 68,905 unvested performance based restricted stock units for which the performance period has been satisfied. These performance based restricted stock units vest over a three year period, in which 33.33% of the units vest each year. The satisfaction of the 2024 performance based restricted units tied to earnings before interest, taxes, depreciation, and amortization ("EBITDA") and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2025 and will be reported at the time of vesting. The satisfaction of the 2022, 2023 and 2024 total shareholder return performance based restricted stock units and the corresponding number of shares to be issued pursuant to these awards, will not be determined until February 2025, February 2026 and February 2027 respectively, and will be reported at the time of vesting. |
| 4 | Common | Common Stock | 2024-04-03 | M | A | 58,388 | $50.01 | 1,238,283 | D CPEX | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of August 7, 2023. |
| 5 | Common | Common Stock | 2024-04-03 | S | D | 55,276 | $137.18 | 1,183,007 | D CPEX | — | — | (F1) This transaction was effected pursuant to a Rule 10b5-1 trading plan which was approved and became effective as of August 7, 2023. (F2) The price range for the aggregate amount sold by the direct holder is $136.72 - $137.71. The Issuer will upon request by the Staff of the U.S. Securities and Exchange Commission or a security holder of the Issuer provide the full information regarding the number of shares sold at each separate price. |
| 6 | Derivative | Employee Stock Option (right to buy) Holding | 2024-04-03 | M | D | 58,388 | $0.00 | 58,389 | D | $50.01 · — to 2026-01-14 | 58,388 Common Stock | (F10) These options are fully vested. |